CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

MB Healthcare.

Shantel Rodriguez, RN, BSN, Chief Nursing Officer

Inappropriate Antibiotic Prescribing in Long-Term Care Facilities: A Growing Concern

Shantel Rodriguez

Shantel Rodriguez

Infection Control Steward

Antibiotic resistance has become a global health crisis, and inappropriate antibiotic prescribing is a major contributor to this problem. Long-term care facilities (LTCFs) are particularly vulnerable to the overuse and misuse of antibiotics due to a high prevalence of infectious diseases and the complex medical needs of their residents.


Inappropriate prescribing of antibiotics in LTCFs is common and can lead to adverse outcomes such as Clostridium difficile infection, drug toxicity, and increased healthcare costs. According to recent studies, up to 75 percent of antibiotic prescriptions in LTCFs are inappropriate or unnecessary, and up to 25 percent of residents receive antibiotics without a clear indication.


One of the reasons for this high rate of inappropriate prescribing is the lack of appropriate diagnostic tools and guidelines for antimicrobial use in LTCFs. Healthcare providers often rely on clinical judgment to diagnose infections and prescribe antibiotics, which can lead to overdiagnosis and overtreatment. Furthermore, many LTCF residents have chronic comorbidities and are on multiple medications, which can complicate the diagnosis of infections and increase the risk of drug interactions and adverse drug reactions.


Another contributing factor is the lack of strong antimicrobial stewardship programs (ASPs) in many LTCFs. ASPs are essential for promoting the appropriate use of antibiotics and reducing the development of antibiotic resistance. However, many LTCFs do not have the resources or infrastructure to implement a comprehensive ASP, leaving healthcare providers without the necessary support to make informed decisions regarding antibiotic prescribing.


By working together, healthcare providers in LTCFs can help preserve the effectiveness of antibiotics and ensure the health and well-being of their residents.


To address this issue, several strategies have been proposed to improve the appropriate use of antibiotics in LTCFs. One of the most effective approaches is to implement an ASP that includes a multidisciplinary team of healthcare providers, such as pharmacists, infectious disease specialists, and infection preventionists. This team can provide guidance on appropriate prescribing, monitor antibiotic use, and educate healthcare providers and residents on antimicrobial stewardship.


Other strategies include the use of rapid diagnostic tests to improve the accuracy of diagnoses and reduce unnecessary antibiotic prescribing, implementation of infection control measures to prevent spread of infections, and development of guidelines and protocols for antimicrobial use in LTCFs.


Inappropriate antibiotic prescribing in LTCFs is a growing concern that requires urgent attention. Healthcare providers in LTCFs should be encouraged to use evidence-based guidelines like antibiogram report, and diagnostic tools to improve the accuracy of diagnoses and reduce the use of antibiotics when unnecessary. The implementation of ASPs and other strategies can also help promote the appropriate use of antibiotics and reduce the risk of antibiotic resistance. By working together, healthcare providers in LTCFs can help preserve the effectiveness of antibiotics and ensure the health and well-being of their residents.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Antibiotic misuse in long-term care is no longer a clinical nuance but a systemic risk with direct implications for patient safety, cost structures and regulatory scrutiny. This perspective underlines how frontline clinical leadership must drive disciplined prescribing practices to contain resistance and elevate care standards across aging populations.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreviewapac.com/leadership-perspective/shantel-rodriguez-nwid-3024.html